

SEQUENCE LISTING

<110> Novo Nordisk A/S

<120> USE OF LONG-ACTING GLP-1 PEPTIDES

<130> 8545.204-WO

<160> 6

<170> PatentIn version 3.5

<210> 1

<211> 31

<212> PRT

<213> Homo sapiens

<400> 1

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly

20 25 30

<210> 2

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1 agonist

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> This residue is H-His

<220>

<221> MISC_FEATURE

<222> (39)..(39)

<223> This residue is Ser-NH2

<400> 2

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu

1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser

20 25 30

Ser Gly Ala Pro Pro Pro Ser

35

<210> 3

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1 agonist

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (29)..(29)

<223> Aib

<400> 3

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Xaa Arg
20 25 30

<220>
<223> GLP-1 agonist

 $\langle 400 \rangle$ 4

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg His Gly
20 25 30

Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala
35 40 45

Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
50 55 60

<220>
<223> GLP-1 agonist

```
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> L-histidine, D-histidine, desamino-histidine, 2-amino-histidine,
beta-hydroxy-histidine, homohistidine, Nalpha-acetyl-histidine,
alpha-fluoromethyl-histidine, alpha-methyl-histidine,
3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine
```

```

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl)carboxylic
acid, (1- aminocyclobutyl) carboxylic acid,
(1-aminocyclopentyl)carboxylic acid,
(1-aminocyclohexyl)carboxylic acid,

```

```
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Val or Leu
```

```
<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> Ser, Lys or Arg
```

```
<220>
<221> MISC_FEATURE
<222> (13)..(13)
```

<223> Tyr or Gln

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> Leu or Met

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Gly, Glu or Aib

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Gln, Glu, Lys or Arg

<220>
<221> MISC_FEATURE
<222> (19)..(19)
<223> Ala or Val

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Lys, Glu or Arg

<220>
<221> MISC_FEATURE
<222> (21)..(21)
<223> Glu or Leu

<220>
<221> MISC_FEATURE
<222> (24)..(24)
<223> Ala, Glu or Arg

<220>
<221> MISC_FEATURE
<222> (27)..(27)
<223> Val or Lys

<220>
<221> MISC_FEATURE
<222> (28)..(28)
<223> Lys, Glu, Asn or Arg

<220>
<221> MISC_FEATURE
<222> (29)..(29)
<223> Gly or Aib

<220>
<221> MISC_FEATURE
<222> (30)..(30)
<223> Arg, Gly or Lys

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Gly, Ala, Glu, Pro, Lys, amide or absent

<220>
<221> MISC_FEATURE
<222> (32)..(32)
<223> Lys, Ser, amide or absent

<220>
<221> MISC_FEATURE
<222> (33)..(33)
<223> Ser, Lys, amide or absent, provided that this residue is absent
if any of the preceding residues are absent

<220>
<221> MISC_FEATURE
<222> (34)..(34)
<223> Gly, amide or absent, provided that this residue is absent if any
of the preceding residues are absent

<220>

<221> MISC_FEATURE
<222> (35)..(35)
<223> Ala, amide or absent, provided that this residue is absent if any of the preceding residues are absent

<220>
<221> MISC_FEATURE
<222> (36)..(36)
<223> Pro, amide or absent, provided that this residue is absent if any of the preceding residues are absent

<220>
<221> MISC_FEATURE
<222> (37)..(37)
<223> Pro, amide or absent, provided that this residue is absent if any of the preceding residues are absent

<220>
<221> MISC_FEATURE
<222> (38)..(38)
<223> Pro, amide or absent, provided that this residue is absent if any of the preceding residues are absent

<220>
<221> MISC_FEATURE
<222> (39)..(39)
<223> Ser, amide or absent, provided that this residue is absent if any of the preceding residues are absent

<220>
<221> MISC_FEATURE
<222> (40)..(40)
<223> amide or absent, provided that this residue is absent if any of the preceding residues are absent

<400> 5

Xaa Xaa Glu Gly Thr Phe Thr Ser Asp Xaa Ser Xaa Xaa Xaa Glu Xaa
1 5 10 15

Xaa Ala Xaa Xaa Xaa Phe Ile Xaa Trp Leu Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40

<210> 6
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1 agonist

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, -hydroxy-histidine, homohistidine, Nalpha-acetyl-histidine, alpha-fluoromethyl-histidine, alpha-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Ala, Gly, Val, Leu, lle, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1- aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl)carboxylic acid, or

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> Ser, Lys or Arg

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Gly, Glu or Aib

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Gln, Glu, Lys or Arg

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Lys, Glu or Arg

<220>
<221> MISC_FEATURE
<222> (24)..(24)
<223> Ala, Glu or Arg

<220>
<221> MISC_FEATURE
<222> (28)..(28)
<223> Lys, Glu or Arg

<220>
<221> MISC_FEATURE
<222> (29)..(29)
<223> Gly or Aib

<220>
<221> MISC_FEATURE
<222> (30)..(30)
<223> Arg or Lys

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Gly, Ala, Glu or Lys

<220>
<221> MISC_FEATURE
<222> (32)..(32)
<223> Lys, amide or is absent

<400> 6

Xaa Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Xaa Tyr Leu Glu Xaa
1 5 10 15

Xaa Ala Ala Xaa Glu Phe Ile Xaa Trp Leu Val Xaa Xaa Xaa Xaa Xaa
20 25 30